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A comprehensive model for heat-induced radio-sensitisation
Sarah Catharina Br€uningk , Jannat Ijaz, Ian Rivens, Simeon Nill, Gail ter Haar and Uwe Oelfke
Joint Department of Physics, Institute of Cancer Research, Royal Marsden NHSF Trust, Sutton, UK
ABSTRACT
Combined radiotherapy (RT) and hyperthermia (HT) treatments may improve treatment outcome by
heat induced radio-sensitisation. We propose an empirical cell survival model (AlphaR model) to
describe this multimodality therapy. The model is motivated by the observation that heat induced
radio-sensitisation may be explained by a reduction in the DNA damage repair capacity of heated cells.
We assume that this repair is only possible up to a threshold level above which survival will decrease
exponentially with dose. Experimental cell survival data from two cell lines (HCT116, Cal27) were con-
sidered along with that taken from the literature (baby hamster kidney [BHK] and Chinese hamster
ovary cells [CHO]) for HT and combined RT-HT. The AlphaR model was used to study the dependence
of clonogenic survival on treatment temperature, and thermal dose R2 0.95 for all fits). For HT sur-
vival curves (0–80 CEM43 at 43.5–57 C), the number of free fit AlphaR model parameters could be
reduced to two. Both parameters increased exponentially with temperature. We derived the relative
biological effectiveness (RBE) or HT treatments at different temperatures, to provide an alternative
description of thermal dose, based on our AlphaR model. For combined RT-HT, our analysis is restricted
to the linear quadratic arm of the model. We show that, for the range used (20–80 CEM43, 0–12Gy),
thermal dose is a valid indicator of heat induced radio-sensitisation, and that the model parameters
can be described as a function thereof. Overall, the proposed model provides a flexible framework for
describing cell survival curves, and may contribute to better quantification of heat induced radio-sensi-
tisation, and thermal dose in general.
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Introduction
The efficacy of radiotherapy (RT) is limited by the relative
radio-sensitivities of the tumour and normal tissue surround-
ing it. Hypoxic cells are generally more resistant to killing by
ionising radiation than are normoxic ones. Therefore, when
dose escalation is limited by normal tissue toxicity, combin-
ing RT with other treatments in order to sensitise these hyp-
oxic targets may be advantageous. Hyperthermia (HT), i.e.
mild, sustained heating, is considered to be an effective radio
sensitiser [1–5]. Therapeutic ultrasound (ThUS) is a minimally
invasive, non-ionising technique for local tissue heating [6,7].
With this technique it may be possible to deliver HT treat-
ments at higher temperatures, but on a shorter timescale
than is currently used clinically [8]. The synergistic effects of
heat and radiation together with the localised, non-invasive
treatment capability of ThUS, mean that its combination with
RT offers an exciting potential treatment approach.
In order to enable treatment planning for such combined
therapies, however, the underlying biological effects must be
quantified, and models put in place to predict them. For
such models, describing the cellular effects, in terms of
survival curves, are the first requirement. There is ongoing
discussion about the underlying biological mechanisms
which lead to synergistic heat and radiation induced cell
killing. Un- or wrongly-repaired DNA double strand breaks
(DSBs) are considered to be the major cause of radiation
induced mitotic catastrophe, eventually resulting in cell
death. One possible explanation of the enhancement of radi-
ation cell killing by HT may be the inhibition of important
DNA repair mechanisms in cells treated [9–13].
Background
Several mathematical models which describe the observed
cellular response to RT (see reviews e.g. [14,15]), or HT
([16–18]) have been proposed. Of these, the linear-quadratic
(LQ) model [19] and the thermal dose concept [20] are the
most common for RT, HT and ThUS treatment planning.
The empirical LQ-model describes the fraction S of cells
surviving irradiation with a single fraction of dose d, using an
exponential of a second-order polynomial characterised by
two radio-sensitivity parameters, a and b.
SLQ ¼ eðadþbd2Þ ¼ eY (1)
In the original publication, the linear contribution ead
was attributed to DSBs resulting from single-track events,
whereas the quadratic component ebd
2
was introduced to
account for DSBs caused by two-track events. Although the
LQ-model provides a good fit to experimental data in an
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intermediate dose regime (2 10Gy), both higher and
lower doses are less accurately described. Several authors
(e.g. [21–26]) have contributed to the discussion on model-
ling low dose hypersensitivity, or on cell survival in the high
dose range and pro- posed adaptations to the original LQ-
model formula to overcome this limitation.
The negative exponent Y¼ adþ bd2 in Equation (1),
known as the “biological effect”, is a dimensionless quantity
which can be used to compare the biological response to dif-
ferent treatment modalities. The isoeffective ratio of doses D2
and D1 which yield the same bio- logical effect for a refer-
ence modality, and the treatment modality of interest, is
defined as “relative biological effectiveness” (RBE).
RBE ¼ D2
D1
jY¼const (2)
According to this definition, the RBE of two treatments is
a function of the biological effect Y and not constant over
the whole range of the survival curve. The RBE-weighted
dose, RBE  D1, corresponds to the equivalent dose in units
of D2 needed to obtain the same biological effect Y as with
treatment at dose D2.
Although the LQ model has been applied to fit cell survival
curves of treatments, such as RT [19] and HT [27,28], with
adapted parameters, it was designed for one specific treatment
modality, and may therefore not be suitable for describing
multi-modality therapies. In particular, it is not suitable for
describing HT cell survival curves which give surviving fractions
as a function of treatment time at a specific temperature.
Treatment time thus represents the “dose parameter” for HT
treatments. These curves are characterised by a strong shoul-
der followed by an exponentially linear decrease of survival
with heating time t at a characteristic slope D0.
oY
ot
¼ D0 (3)
The LQ-model is unable to describe the shoulder region
of these curves, and overestimates the effect at high (ther-
mal) doses where the quadratic component of the formula
dominates. Therefore, HT survival curves have been described
by the Arrhenius model [29]. This is based on the kinetics of
chemical reactions as described by Arrhenius equations
which describe irreversible processes, expressing the rate
constant k of the reaction as an exponential function of the
ratio of the activation energy Ea, and the thermal energy (the
product of temperature T and universal gas constant R)
[20,30–32].
k ¼ Ae EaRT (4)
A is a characteristic of the system studied. For HT survival
curves, the rate constant k (in min1) corresponds to the
inverse final slope of the curve, D0
1 [29]. The Arrhenius
model therefore provides a description of HT cell survival
only in the exponentially linear decay region of the survival
curve, the initial shoulder of the curve is not covered by this
model description.
In order to allow calculation of biologically equivalent
times for HT treatments at different temperatures, and to
sum up the effects of inhomogeneous heating profiles, the
thermal dose concept [20] was introduced. This is a two case
model which expresses heating times tX at a temperature TX
in terms of “thermal dose” (or CEM43), i.e. equivalent heating
time at 43 C, t43. “Thermal dose” therefore represents a con-
cept of calculating an RBE-weighted treatment time for HT
treatments.
t43 ¼ tX  R43 CTX with R ¼ 0:25 TX  43
C
0:5 TX > 43 C

(5)
The parameter R in Equation (5) depends on temperature
and the cell line specific activation energy of the underlying
chemical reaction as described by Arrhenius equations.
Despite these cell line and temperature dependencies, con-
stant values of 0.5 and 0.25 are commonly assumed for R for
temperatures ranging from 41 to 45 C as indicated in
Equation (5). Importantly, due to the exponential relation of
thermal dose, for high temperatures, deviations in R from an
approximation of a constant value of 0.5 may significantly
influence the calculated thermal dose values and deviate
from actual thermal damage [33]. A constant parameter R
also means that RBE would be independent of the underly-
ing biological effect in this case. Although separate models
exist for both RT (LQ-model), and HT (Arrhenius model) cell
survival curves, to date no unifying mathematical model
description has been proposed. We introduce a modified LQ-
model which is able to both describe RT and HT cell survival
curves and combinations thereof. The model is validated
using a set of previously published cell survival curves, as
well as our own data set for single and combination treat-
ments for a temperature range of interest to ThUS mediated
HT (45–48 C).
Methods
The AlphaR model
Model formulation
Heat-induced radio-sensitisation is believed to be mainly due
to an inhibition of DNA repair mechanisms. Thus, for com-
bined RT-HT treatments, a model that reflects this hypothesis
is of interest. In the proposed model, we consider the oppos-
ing actions of induced damage and its repair. If there were no
cellular repair mechanisms, cell survival plotted on a log scale
would decrease linearly as a function of treatment “dose” per
fraction D, i.e. radiation dose or heating time, with a charac-
teristic slope a0. The underlying damage mechanism could be
of an arbitrary origin and might actually be a combination of
DNA and other cellular damage, e.g. to the membrane or cel-
lular proteins. Importantly, cells will counteract this damage
using a number of repair mechanisms which in turn will be
treatment dependent, and are here described by a function
FR (D). The slope of the cell survival curve (on a log scale), oY,
is therefore the sum of damage and repair contributions:
dY
dD
¼ a0  FR Dð Þ (6)
Mathematically, the simplistic approximation for describ-
ing the repair function is the approximation with a Taylor
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series up to linear order:
FR Dð Þ ¼ aR  2bD D  DT ¼
aR
2b
0 D > DT
8<
: (7)
Here, aR represents the rate of damage compensation,
which is counteracted by a dose-dependent term 2bd, i.e.
damage to the repair potential. There is therefore a limiting
dose, DT ¼ aR/(2bd), up to which repair mechanisms are
active (FR (D)> 0). For treatments with doses exceeding DT,
FR (D) is 0 (negative values of FR are not meaningful).
Integrating the slope of the survival curve given in
Equation (6) and using the repair function FR (D) as defined
in Equation (7) results in an expression of the biological
effect, Y, as a function of dose described by a two case
model:
Y Dð Þ ¼
ðD
0
dY
dD0
dD0 ¼
ða0  aRÞDþ bD2 D  DT
a0D a
2
R
4b
D > DT
8<
: (8)
Below the threshold dose, DT, the survival curve has a lin-
ear quadratic behaviour with parameters a¼ a0 aR and b.
At doses exceeding DT, no further repair is possible and cell
survival is described by a single exponential.
Experimental procedure
Cell lines and culture conditions
The human cancer cell lines, HCT116 (colorectal carcinoma),
and Cal27 (squamous cell carcinoma) were used to generate
cell survival curves for testing the model presented. HCT116
cells were cultured in McCoy’s 5 A medium (Gibco, Paisley,
UK) containing 1% antibiotics (50 U/ml each of penicillin,
streptomycin B and Amphotericin B (Sigma, Poole, UK)),
Cal27 cells were grown in DMEM (Gibco, Paisley, UK). All
media were supplemented with 10% fetal bovine serum
(PAN Biotech, Wimborne, UK). Cells were grown in T80 cul-
ture flasks in a humidified atmosphere with 5% CO2 at 37 C
and passaged twice a week using Accutase (Gibco, Paisley,
UK). For experiments, cells in exponential growth phase
between passages 5 and 20 were used. Regular screening for
mycoplasma and bacterial contamination was performed.
Cell treatments
Cells were detached from the flask, counted and concen-
trated to give a cell suspension of 5106 cells per ml in
complete growth medium. 60 ll volumes of cell suspension
were transferred to 150 ll thin walled polymerase chain reac-
tion (PCR) tubes (VWR, Lutterworth, UK). For irradiation,
sealed tubes were placed in customised blocks of solid water
in a small water bath at room temperature. This allowed for
reproducible localisation of the cells 1 cm deep in (solid)
water in the centre of the open field of a small animal irradi-
ation research platform (SARRP, X-Strahl, Camberly, UK). The
machine was operated at 220 kVp, and a 1mm copper filter
was used to harden the beam. The dose rate used was
63.5 mGy/s at the PCR tube location. Monte Carlo simulations
and absolute dose measurements were performed to verify
the intended dose delivery.
For thermal exposure, cell containing tubes were placed
in the central wells of a Biorad Tetrad2 DNA Engine PCR ther-
mal cycler (Hercules, CA), and underwent a three step heat-
ing protocol as described in [34]. Plateau heating
temperatures and durations ranged from 45 to 48 C, and
1–80min, respectively. Heating profiles were verified as
described in [34]. A minimum heating time of one minute
was chosen, in order to minimise the contribution of thermal
effects from heating and cooling gradients to the total ther-
mal dose received by the sample.
For combination treatments, cells were irradiated first,
since our pilot control experiments confirmed that the radio-
sensitising effect was more pronounced in this order for the
cell line used (data not shown). Cells were placed on ice
before, after, and between, treatments to minimise cellular
activity. Time between treatments was recorded and kept to
a maximum of 20min. It was confirmed that there was no
significant difference in clonogenic cell survival for time inter-
vals up to 35min between irradiation and heat application.
Clonogenic assay
After treatment, the cells were plated in triplicates in 6-well
plates, or 9 cm Petri dishes, for colony forming assays.
Seeding densities were adjusted to yield a final number of
approximately 50 colonies per well. These ranged from 50 to
5105 cells/well. To prevent variations in plating efficiency
due to different seeding densities in the wells, differences in
seeding densities were accounted for by the addition of irra-
diated (48 Gy) feeder cells [35] of the same cell line to yield a
final cell seeding density of 104 cells/cm2. Feeder cells were
allowed to attach overnight before treated cells were added.
Control plates containing only irradiated feeder cells were
plated for each experiment to ensure that no colonies arose
Table 1. Summary of the 42 cell survival data sets used in this study. Indicated are the cell line, treatment duration t at temperature T, and radiation dose
range D. For all combination treatments of RT and HT, RT was delivered first.
HCT116 Cal27 BHK [36] CHO [37]
t [min] T [C] D [Gy] t [min] T [C] D [Gy] t [min] T [C] D [Gy] t [min] T [C] D [Gy]
0–56 45 – 0–80 45 – 180 43.5 – 20,30,40,60,80 43 0–8
0–28 46 – 0–40 46 – 50 46 – 20 44 0–8
0–14 47 – 0–20 47 – 1 50 – 10,15,20 45 0–8
0–7 48 – 0–10 48 – 0.1 54 – 6,9 46 0–8
1.25 48 0–6 1 48 0–6 0.01 57 –
1.25,2.5,3.75,5 47 0–6 1,2,3,5 47 0–6
2.5,5,7.5,10 46 0–6 4 46 0–6
5,10 45 0–6 8 45 0–6
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from these. Plates were incubated for 9–12 d to allow colony
formation.
After macroscopically visible colonies had formed, the cul-
ture medium was removed, and colonies were gently rinsed
with PBS before being fixed using ice cold 100% methanol.
Dried plates were stained with 0.5% Gentian Violet solution
in water (Sigma-Aldrich, Schnelldorf, Germany), and washed
with tap water to remove unbound stain. Colonies in dried
plates were scored if they exceeded a threshold number of
50 cells. Wells with overlapping colonies were excluded from
the analysis.
To obtain cell surviving fractions, colony numbers were
normalised to the number of cells seeded, as well as to the
plating efficiency of the untreated controls, or, in the case of
combination treatments, the number of colonies arising
when cells were solely thermally exposed. Results from at
least three independent repeats were averaged for each data
point. Besides the data sets obtained experimentally for
HCT116, and Cal27 cells, cell survival data for baby hamster
kidney (BHK) [36] and Chinese hamster ovary cells (CHO) [37]
cells from the literature were analysed. Table 1 gives an over-
view of the cell survival data used, and the corresponding
treatments.
Data analysis and model fitting
All cell survival data shown are mean values, with standard
deviations indicated as error bars (if exceeding the symbol
size). In the case of CHO cells, the symbol size of most of the
published survival data exceeded the size of potential error
bars, which were quoted as standard errors of the mean [37].
Thus, no error bars could be provided for these data sets.
Cell survival data sets were fitted to the AlphaR, and the LQ-
model using a nonlinear least squared fit in MATLAB
(MathWorksVR , Natick, MA). Fits were performed on averaged
data weighted using the uncertainties of each data point
(weighting factor w ¼ meanðSÞstdðSÞ
 2
). The fit parameters
obtained were further analysed for their time and tempera-
ture dependence using the same fitting approach, and are
always given with 95% confidence bounds.
Results
Hyperthermia treatments
Comparison of the AlphaR and the LQ-model
HT cell survival curves are characterised by an exponentially
linear descent following an initial shoulder region. When
comparing the fits of the LQ and the AlphaR model (selected
results shown in Figure 1) it is clear that the AlphaR model
provides a good fit, in both the shoulder and exponential
decay regions of the curve, whereas the LQ model cannot
describe such a behaviour and overestimates cell killing at
high thermal doses.
For all cell lines studied, in the case of HT treatments aR
equals a0. The number of free model parameters therefore
reduces to two in this case, namely a0 and b. Although this
is the same number of parameters as used by the LQ-model,
the AlphaR model provides the better fit in terms of
coefficients of determination (R2AlphaR¼ 0.99, R2LQ¼ 0.98).
This was expected as the LQ-model represents a sub case of
the AlphaR model and fits will therefore always be inferior,
or equal to the AlphaR model.
Comparing treatments at different temperature
Figure 2 shows survival curves for HCT116, Cal27 and BHK
cells fit by the AlphaR model together with the correspond-
ing temperature dependences of a0 and b. The increase of
the fit parameters with temperature is well described by an
exponential.
a0 Tð Þ ¼ a1  ea2 T43Cð Þ
b Tð Þ ¼ b1  eb2ðT43CÞ (9)
For BHK cells, a very large range of treatment tempera-
tures was covered (43.5 57 C), resulting in tight 95% confi-
dence intervals for the exponential fits.
Expressing thermal dose in terms of the AlphaR model
For HT treatments the RBE, see Equation (10) is defined as
the isoeffective ratio of treatment times, tT, at temperature, T,
and the equivalent time at the reference temperature 43 C,
t43. Using the AlphaR model, and assuming the threshold
doses DT (43 C) of heating at 43 C to be lower than the
threshold at higher temperatures DT (T), this ratio is
expressed as:
RBE Tð Þ ¼ tT
t43
jY ¼ const (10)
For a given biological effect Y Equation (8) can be solved
for the treatment time (indicated as ‘D’ in Equation (8)) pro-
viding a description of RBE as a function of the biological
effect using the AlphaR model parameters if this expression
is inserted in the above Equation (10).
In their thermal dose concept, Sapareto and Dewey
assumed a constant RBE over the whole range of the survival
curve. The AlphaR model description of RBE is, however, not
Figure 1. Comparison of the fit of HT (48 C) cell survival data of HCT116 cells
by the AlphaR (solid line) and LQ (dashed line) model. In contrast to the
LQ model, the AlphaR model follows the initial shoulder and exponentially
linear decay of the data. The corresponding coefficients of determination
(R2AlphaR¼ 0.99, R2LQ¼ 0.98) further support this observation.
4 S. C. BR€UNINGK ET AL.
independent of the biological effect unless the ratio a
2
0
b was
constant for a specific temperature, i.e. independent of the
underlying biological effect.
if
a20
b
¼ const ! RBE Tð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
bð43 CÞ
bðTÞ
s
¼ a0ð43
CÞ
a0ðTÞ (11)
For the exponential temperature dependence of a0 and b
described in Equation (9), this condition for constant RBE
would be fulfilled if the relation between the exponents
b2 ¼2a2 is valid.
a20
b
¼ a
2
1
b1
eð2a2b2ÞðT43
CÞ ¼ const if 2a2 ¼ b2 (12)
For the cell lines studied, the ratios of b2 and 2a2 with
95% confidence bounds were 0.74 ± 0.33 (HCT116),
1.18 ± 0.38 (Cal27) and 0.98 ± 0.12 (CHO). Within the range
of uncertainties of the fit parameters, RBE may therefore be
constant over the whole range of the survival curve. We
therefore re-analysed the cell survival data under the con-
straint of a constant ratio of a
2
0
b . For each cell line studied, the
parameter ratio which provided the best overall fit to all sur-
vival curves at different temperatures in terms of the sum of
the coefficients of determination of all survival curves was
applied. Under this constraint all survival data could be fitted
with coefficients of determination exceeding 0.95, and Figure 3
shows the resulting temperature dependencies of a0. The
thermal dose parameter R (see Equation (5)) can now be
Figure 2. HT cell survival curves at various treatment temperatures of three different cell lines (top: HCT116, middle: Cal27, bottom: BHK [36]) fit by the AlphaR
model. The corresponding fit parameters, a0 and b, are plotted as a function of the difference of the heating temperature and 43 C. This dependence is well
described by an exponential fit (solid line, 95% confidence bounds are shown as dashed lines) with the parameters of this exponential (a1 and a2, or b1 and b2)
being shown here with the corresponding 95% confidence bounds.
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expressed in terms of the model parameter:
R ¼ ea2 ¼ 0:51 0:48; 0:54ð Þ for HCT116
R ¼ 0:46 0:54; 0:38ð Þ for Cal27
R ¼ 0:582 0:580; 0:584ð Þ for BHK
(13)
Thermo-radio-sensitisation
Influence of the heating protocol
In order to quantify the radio-sensitising effects of different
time-temperature combinations applied after irradiation, cell
survival curves obtained with a constant thermal dose but
different heating temperatures and duration are compared
for CHO and HCT116 cells (see Figure 4). There was no statis-
tically significant difference between cell survival curves
obtained with a range of heating combinations for thermal
doses between the 20–80 equivalent minutes tested for
HCT116, and 40 equivalent minutes for CHO cells. The radio-
sensitising effect is therefore considered to be the same over
the temperature range covered and may be quantified by
thermal dose.
Thermo-radio-sensitisation modelling with the AlphaR
model
Examples of survival curves for irradiated and heated HCT116
cells are shown in Figure 5 together with the corresponding
fits using the AlphaR model. Due to the experimental limita-
tions that prevented the treatment of more than 106 cells
simultaneously, the data range provided does not cover the
exponentially linear regime of the cell survival curve. This
means that the fit of a0 and aR is prone to large uncertain-
ties, making it impossible to draw conclusions about the indi-
vidual thermal dose dependencies of these parameters. We
therefore restrict the discussion to the LQ branch of the
AlphaR model (see Equation (8) for doses below the thresh-
old DT). The thermal dose dependence of a (a¼ a0  aR) and
b is analysed for all RT-HT survival curves indicated in
Table 1. Thermal dose (t43) was calculated according to
Equation (5) using the values of the thermal dose parameters
R calculated in Equation (13) for HCT116 and Cal27 cells.
Since such data was not available for CHO cells, here a value
of 0.5 was used for R as suggested in the original thermal
dose description.
Whereas a steady increase of a with thermal dose is
observed, there is no clear correlation between b and ther-
mal dose. We therefore re-fit the data under the assumption
of a constant b and used the values obtained from a fit of
the RT curve without heating (bHCT 116¼ 0.042Gy2,
bCal27¼ 0.043Gy2, bCHO¼ 0.046Gy2). The corresponding
coefficients of determination were >0.95 for all fits, indicat-
ing that the assumption of a constant b still provides accept-
able fits to the cell survival data. The respective results for a
are shown in Figure 6 (left) and display a linear increase with
thermal dose. The same fitting approach was applied to CHO
and Cal27 cell survival data. The thermal dose dependencies
of a for these cell lines are shown in Figure 6 (middle and
right).
Discussion
For both treatment modalities, HT and RT, individual model
approaches have been proposed in the past and used to
describe the respective cell survival curves. While the charac-
teristic continuously bending RT cell survival curves are well
described by the linear quadratic model in the intermediate
dose regime (1 10Gy), the Arrhenius model has fre-
quently been used to describe heat-induced cell toxicity.
Although both models work reasonably well for their individ-
ual treatment modality, they are not applicable to other
treatment modalities.
This motivates the need for a unifying model capable of
describing cell survival curves of arbitrary origin. The advan-
tage of the AlphaR model over existing modelling
approaches is its flexibility to describe cell survival curves of
both of these treatment modalities accurately. Moreover, the
AlphaR model overcomes some of the limitations of the indi-
vidual cell survival models, such as the description of the
whole HT survival curve, including its strong shoulder which
cannot be modelled by the Arrhenius equation. This model
should also improve quantification of heat induced radio-sen-
sitisation, and the understanding and interpretation of ther-
mal dose in general, which are of particular importance for
combination therapies as discussed in this article. The AlphaR
Figure 3. Temperature dependence of a0 fit to HT cell survival curves of HCT116 (left), Cal27 (middle), and BHK (right) cells under the constraint of a constant ratio
a20
b as indicated.
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model provides great flexibility in modelling cell survival
curves of various origins. It was motivated by the action and
counter action of cellular damage and repair mechanisms.
This is of particular interest for an application of the model
to combination therapies of HT and RT, since one of the key
effects responsible for the synergistic effect of these treat-
ments is a reduction in repair capacity due to the inhibition
of important pathways [9,11].
The AlphaR model provides a simple mathematical
description that does not necessarily require more fit param-
eters than the widely used linear quadratic model to provide
fits of equal or better quality – here evaluated in terms of
coefficients of determination. For the analysis of model
parameters as a function of heating duration and/or tem-
perature, it is essential to evaluate several treatment combin-
ation data sets originating from different cell lines. In this
Figure 4. Comparison of HCT116 and CHO [37] cell survival curves for combination treatments of RT and HT for the same thermal dose (20–80 CEM43), but differ-
ent heating temperatures and durations as indicated in the legends. Cell survival data were normalised to 100% after HT treatment. Within the range of uncertain-
ties of the clonogenic assay, there is good agreement between data sets originating from different time/temperature combinations.
Figure 5. Selected RT-HT cell survival curves of HCT116 cells heated at various times at 47 C fitted by the LQ part of the AlphaR model (left). For better visualisa-
tion of the data, curves are shown with the respective off set in survival after HT treatments. The corresponding fit parameters a (middle) and b (right) for all sur-
vival curves listed in Table 1 are shown as a function of thermal dose. Thermal dose t43 was calculated according to Equation (10) under the assumption of a
constant RBE calculated using Equation (11), and the respective values for a0 as indicated in Figure 3.
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work clonogenic survival curves for two cell lines (HCT116
and Cal27) were measured for a number of treatment combi-
nations. As a comparison for each treatment modality an
additional data set from the literature [36,37] was considered.
Although it would be desirable to include even more data in
this analysis, this was difficult because of the lack of consist-
ent data in the literature.
For HT treatments, the AlphaR model describes the shape
of the survival curve well in both the shoulder and the expo-
nential decay region using only two fit parameters. In this
case aR was found to be equal to a0. This may imply that
below the threshold heating time DT (see Equation (7)) ther-
mal damage would be reversible if repair were fully func-
tional, whereas the damage is irreversible for treatment times
exceeding DT.
The temperature dependence of a0 and b for HT treat-
ments at different temperatures followed an exponential. The
model parameters a0 and
ﬃﬃﬃ
b
p
can therefore be interpreted as
rate constants of chemical reactions as described by
Arrhenius equations. With this description it was possible to
provide a description of the RBE-weighted, i.e. “thermal”,
dose as a function of heating time and duration. Due to rela-
tively large uncertainties in the fit parameters obtained, it
was not possible to prove that RBE may not be constant
over the whole range of the survival curve as assumed by
Sapareto’s and Dewey’s thermal dose concept. However, it
would not be surprising if there was a change in RBE
between the shoulder and exponential decay region of the
survival curve due to potential changes in the cellular
response pathways activated, or the overcoming of activation
energies of protein denaturation. In such a case, the AlphaR
model could provide the mathematical tools for calculating
RBE at various stages along the survival curve. Further ana-
lysis of more cell survival data, in particular of different cell
lines is needed to better understand the relation between HT
treatments at different temperatures and to accurately sum-
marise complex heating profiles. The data sets used in this
analysis were fitted well (i.e. coefficients of determination R2
always >0.95) under the assumption of a constant RBE over
the whole range of the survival data. This assumption further
reduced the number of free model parameters to one (a0),
however, the constant ratio a
2
0
b used was cell line dependent
(a
2
0
b HCT116ð Þ ¼ 1:95;
a20
b (Cal27)¼ 3.0,
a20
b BHKð Þ ¼ 4:2), and
could only be obtained from the analysis of multiple HT cell
survival curves at different temperatures.
For combination treatments, the range of the data pro-
vided was not sufficient to determine all parameters of the
AlphaR model, since it did not cover the exponentially linear
regime of the survival curve needed for the determination of
a0. Analysis of the data for combination treatments therefore
had to be restricted to the LQ branch of the AlphaR model
which is applicable for treatment doses below the threshold
dose DT (see Equation (7)). It is important to note, that for
combination treatments, survival was normalised to 100%
after heat treatment alone. The AlphaR model is able to
describe the surviving fraction correctly both after heat treat-
ments alone (i.e. the offset of on the y-axis of the curve) and
as a function of additional radiation dose. This is another
indication of why the AlphaR model may be preferable over
a pure LQ-model. Considering that the synergism between
heat and radiation may be due to an inhibition of DNA dou-
ble strand break repair, it might be a valid assumption to use
a constant value for the a0 parameter independent of the
heating time and duration used. In this case, a potential
increase of a with thermal dose may be due to a reduction
in the repair capacity of the cell, i.e. a reduction of aR.
However, it was not possible to test this hypothesis with the
data provided. Limitations in the range of surviving fractions
covered were due to the experimental procedure for clono-
genic assays and the cell lines used. In order to obtain data
points for surviving fractions on the order of 106, several
million cells have to be treated homogeneously (i.e. obtain
the same (thermal) dose) and plated in the same dish at the
correct seeding density to provide a sufficient number of
countable colonies. With the experimental set-up used, this
was, however, not feasible due to a limited number of PCR
tubes that could be treated simultaneously. Other cell lines
may be easier to analyse if they display an earlier transition
to the exponentially linear regime of the cell survival curve.
The observation that a transition to an exponential linear
dose dependence should occur for radiation treatments is
described in detail e.g. in [38,39].
Figure 6. Fitparameter a as a function of thermal dose given in addition to RT treatment. Thermal dose was calculated according to Equation (5) using the values
of R calculated in Equation (13). The parameter roughly follows a linear increase with thermal dose. The fit was performed under the constraint of a constant value
b as indicated in this figure. For all data sets the resulting coefficients of determination R2 were greater than 0.95 (survival curves are not shown).
8 S. C. BR€UNINGK ET AL.
Several groups have previously reported on describing the
effects of heat induced radio- sensitisation by the LQ-model.
However, there is currently ongoing discussion about the
heating time and temperature dependence of the LQ model
parameters. Consistent cell survival curve data covering a
broad range of thermal doses from various time temperature
combinations (as e.g. given in [37]) are rare, making it diffi-
cult to evaluate dependencies. To date, several approaches
have been proposed: Dikomey et al. reported a linear
dependence of both a and b on heating time at a specific
temperature, but drew no conclusions about unifying ther-
mal dose dependence. Later, Xu et al. [40,41] reported
increasing values of a, but observed no change in b for
human NSY and HCT15 cells treated with mild HT (41.1 C,
1 h). This approach was adapted by Myerson et al. for their
study of clinical results of patient response modelled with
the assumption of a constant b parameter [42]. More
recently, Franken et al. have reported both increasing and
decreasing values of a with heating temperature [43].
Modelling studies requiring heating time and temperature
dependent LQ parameters for equivalent dose calculations of
patient treatment plans for RT-HT combination treatments,
have applied a number of model descriptions: Linear and
exponential increase of a with treatment mean temperature
but constant b [27]; Piece-wise interpolated parameters [28];
exponential increase of both a and b with treatment tem-
perature [44]. Except for the study conducted by Dikomey
et al. all of these applications focused on mild HT applica-
tions with temperatures ranging between 39 and 43 C. Our
data analysis suggests that, for the cell lines and thermal
dose range studied (at temperatures exceeding 43 C), ther-
mal dose may be a good indicator of the degree of radio-
sensitisation achieved. But it is indeed difficult to define a
specific thermal dose dependence of a and b, i.e. linear,
exponential or no increase with thermal dose. This may be
due to the fact that very similar cell survival data sets may
lead to different fit results since changes in one parameter
may partially be accounted for through the other parame-
ter(s). We therefore decided to minimise the number of free
parameters by assuming a constant value for b. Despite this
simplification, it was still possible to describe the survival
data reasonably well (R2 always >0.95). The ambiguity of the
model fit is particularly clear in the case of CHO cells for
which a linear increase of b with heating time was originally
reported. Therefore, care should be taken when reporting
thermal dose dependencies of model parameters, and mini-
misation of the number of parameters should be considered
by applying reasonable simplifications as proposed in this
case.
Although this article, and the proposed AlphaR model
focus entirely on the cellular response of RT, HT and RT-HT
treatments in terms of clonogenic cell survival in vitro, it is
important to note, that direct cytotoxicity and radio sensitisa-
tion at a cellular level are not the only biological effects
associated with such treatment combinations. In general,
heat-induced cellular effects are expressed as damage to
cytoplasmic, membrane and cytoskeletal proteins [9,12,45].
Significant damage to these proteins may induce apoptotic
and/or autophagic pathways, whereas uncontrolled
coagulation necrosis only occurs in response to temperatures
exceeding 50 C [34]. The conformation of proteins and lipids
is affected by the ambient temperature, which in turn influ-
ences a protein’s functionality. While lipid aberrations are
reversible, they may still affect the rate of protein aggrega-
tion, which is considered to be the major cause of heat
induced cell death [12,46]. The acute cellular response to
heat shock is expressed as an increased synthesis of molecu-
lar chaperones (heat shock proteins [Hsp]) that assist in pro-
tein folding and can compensate for the increased number
of misfolded proteins produced. This enables prolonged sur-
vival of the cell at elevated temperatures and may explain
the build up of thermo tolerance.
Besides biological effects on a cellular level, a number of
physiological effects have been reported for HT treatments
in vivo. These include changes to the tumour micro-environ-
ment (such as pH), enhanced tissue perfusion and vascular
changes which may enhance tissue- reoxygenation, as well
as the activation of immunological response mechanisms
[47–49] (see e.g. [50] for a detailed review). In contrast to the
proposed thermal dose concept for cytotoxic effects in vitro,
which allows for a conversion of treatment times at different
temperatures to those at 43 C, these physiological effects
may indeed be dependent on the specific temperature
regime, making a comparison of treatments in vivo at differ-
ent temperatures difficult. In particular, alterations in tumour
oxygenation may greatly influence the effect of heat-induced
radio-sensitisation. Whereas mild HT will enhance tissue per-
fusion and improve tissue re-oxygenation, resulting in a more
effective cell kill upon irradiation, ablative techniques, such
as high intensity focussed ultrasound therapy may result in
vessel occlusion and oxygen depletion in the tissue. Similarly,
the activation of the immune response may already be acti-
vated at non-lethal temperatures in the fever range, but dif-
ferent immunomodulatory effects may be present at
cytotoxic temperatures (>43 C) [47].
In order to predict and plan treatment response to com-
bination treatments of HT and RT in patients, it is therefore
important to take both cellular and physiological effects into
account. Correct modelling of the biological effects on a cel-
lular level in vitro may therefore only be considered a first
step towards more sophisticated treatment planning.
Conclusions
The proposed AlphaR model was suitably accurate for
describing cell survival curves originating from HT, RT treat-
ments and their combination. The new model overcomes
some of the limitations of the LQ model, and provides
equivalent or better fits of cell survival curves, which could
be quantified in terms of superior coefficients of determin-
ation. It was possible to relate the model parameters to exist-
ing concepts of thermal dose, and to express them as a
function thereof. This formulation therefore holds great
potential for future treatment planning applications of
focussed ultrasound mediated heating in combination with
RT, and may in general be of interest for application to a
wide range of combinative treatment modalities.
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